Re-Entering Antibacterial Drug Development Summit



According to the Centers for Disease Control and Prevention, antibiotic-resistant infections are associated with an additional 23,000 deaths and 2 million illnesses in the United States each year. The estimated annual impact of antibiotic-resistant infections on the national economy is $20 billion in excess direct health care costs, and as much as $35 billion in lost productivity from hospitalizations and sick days. By holding the Re-Entering Antibacterial Drug Development Summit, we at Cambridge Healthtech Institute are trying to contribute to the efforts to revive antibacterial pipeline, and to improve antimicrobial stewardship in the United States and worldwide. This Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders, who are shaping the current state of antibacterial discovery and development.

2015 Conference at a Glance

Antibacterial Research and Development

Novel Monoclonal Antibodies for the Prevention and Treatment of Bacterial Infections.

Steven ProjanSteven J. Projan. Ph.D., Senior Vice President, R&D, Innovative Medicines unit, Head of Infectious Diseases & Vaccines, Medimmune

 

Antibiotic Adjuvants To Reclaim Legacy Drugs

Gerard WrightGerard D. Wright, Ph.D., Director, Michael DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Canada Research Chair in Molecular Studies of Antibiotics

 

Bringing The Full Power Of Chemical Synthesis To Bear On The Discovery Of New Antibiotics

Andrew MyersAndrew G. Myers. Ph.D., Amory Houghton Professor of Chemistry, Department of Chemistry & Chemical Biology, Harvard University

 

Gram-Negative Antibiotics: The Importance Of Compound Properties For Drug Discovery

Heinz MoserHeinz E. Moser, Ph.D., Executive Director – Chemistry Infectious Diseases, Global Discovery Chemistry, Novartis Institutes for BioMedical Research

 

View Full Agenda


Clinical Development and Commercialization of Antibacterials

Overcoming The Challenges Of Developing New Antibiotics For Resistant Bacteria With Regulatory Support And New Diagnostics

Barry EisensteinBarry Eisenstein, M.D., Senior Vice President, Scientific Affairs, Merck

 

Achieving Value and Improving Patient Safety Through Innovative Methods of Antimicrobial Utilization - Experience At the Front Line of Care

Ronald NahassRonald G. Nahass, M.D., MHCM, President, ID Care

 

New Business Models For Antibiotics: A Summary Of Recent Initiatives And Possible Future Directions

John RexJohn Rex, M.D., Vice President and Head, Infection, Global Medicines Development, AstraZeneca

 

View Full Agenda


Diagnostics to Guide Antimicrobial Stewardship and Drug Development

Latest Advances in Pathogen Detection

Kimberly HansonKimberly E. Hanson, M.D., Medical Director, Mycology, Mycobacteriology, and Virology Laboratories, Section Chief, Microbiology, ARUP Laboratories

 

The Role Of The Microbiology Laboratory In Antimicrobial Stewardship Programs

Joint Presentation:

Karen CarrollKaren C. Carroll, M.D., Director, Division of Microbiology, Department of Pathology, The John Hopkins Hospital

 

Edina AvdicEdina Avdic, Pharm.D., MBA, Clinical Specialist, Infectious Diseases, Associate Director, Antimicrobial Stewardship Program, The John Hopkins Hospital

 

View Full Agenda




For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5496
Email: mfilshtinsky@healthtech.com


For exhibit & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-5412, Fax: (781) 972-5470
email: cbenton@healthtech.com



By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs